Advertisement
AXGN vs XRAY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXGN is a Hold and XRAY is a Buy.
Momentum Indicator for AXGN turns positive, indicating new upward trend
AXGN saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 73 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AXGN's RSI Oscillator exited the oversold zone, 18 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for AXGN just turned positive on October 20, 2026. Looking at past instances where AXGN's MACD turned positive, the stock continued to rise in 33 of 47 cases over the following month. The odds of a continued upward trend are 70%.
Following a +4.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXGN advanced for three days, in 271 of 329 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
AXGN moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
AXGN broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AXGN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.705) is normal, around the industry mean (3.837). P/E Ratio (-56.746) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). AXGN has a moderately high Dividend Yield (0.105) as compared to the industry average of (0.010). P/S Ratio (8.961) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. AXGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
XRAY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for XRAY turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 32 of 53 cases over the following month. The odds of a continued upward trend are 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XRAY's RSI Indicator exited the oversold zone, 21 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 49 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
Following a +7.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for XRAY moved below the 200-day moving average on September 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
XRAY broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.361) is normal, around the industry mean (4.942). P/E Ratio (-3.377) is within average values for comparable stocks, (37.224). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.069) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
AXGN | XRAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 38 | 100 | |
SMR RATING 1..100 | 95 | 97 | |
PRICE GROWTH RATING 1..100 | 46 | 64 | |
P/E GROWTH RATING 1..100 | 35 | 16 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXGN's Valuation (4) in the Medical Specialties industry is in the same range as XRAY (6). This means that AXGN’s stock grew similarly to XRAY’s over the last 12 months.
AXGN's Profit vs Risk Rating (38) in the Medical Specialties industry is somewhat better than the same rating for XRAY (100). This means that AXGN’s stock grew somewhat faster than XRAY’s over the last 12 months.
AXGN's SMR Rating (95) in the Medical Specialties industry is in the same range as XRAY (97). This means that AXGN’s stock grew similarly to XRAY’s over the last 12 months.
AXGN's Price Growth Rating (46) in the Medical Specialties industry is in the same range as XRAY (64). This means that AXGN’s stock grew similarly to XRAY’s over the last 12 months.
XRAY's P/E Growth Rating (16) in the Medical Specialties industry is in the same range as AXGN (35). This means that XRAY’s stock grew similarly to AXGN’s over the last 12 months.
| AXGN | XRAY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | 1 day ago 50% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 60% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 74% |
| Advances ODDS (%) | 6 days ago 82% | 7 days ago 59% |
| Declines ODDS (%) | 1 day ago 82% | 3 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXGN’s FA Score shows that 1 FA rating(s) are green while XRAY’s FA Score has 2 green FA rating(s).
- AXGN’s FA Score: 1 green, 4 red.
- XRAY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXGN’s TA Score shows that 4 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).
- AXGN’s TA Score: 4 bullish, 5 bearish.
- XRAY’s TA Score: 4 bullish, 5 bearish.
Price Growth
AXGN (@Medical/Nursing Services) experienced а +3.57% price change this week, while XRAY (@Pharmaceuticals: Other) price change was +5.41% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.51%. For the same industry, the average monthly price growth was -8.28%, and the average quarterly price growth was -7.48%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.35%. For the same industry, the average monthly price growth was -3.01%, and the average quarterly price growth was +10.29%.
Reported Earning Dates
AXGN is expected to report earnings on Oct 28, 2026.
XRAY is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.51% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.35% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
AXGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXGN has been loosely correlated with XRAY. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if AXGN jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To AXGN | 1D Price Change % | ||
|---|---|---|---|---|
| AXGN | 100% | -1.47% | ||
| XRAY - AXGN | 36% Loosely correlated | +1.41% | ||
| ITGR - AXGN | 31% Poorly correlated | +0.17% | ||
| CLPT - AXGN | 31% Poorly correlated | +7.19% | ||
| GMED - AXGN | 31% Poorly correlated | -1.14% | ||
| ICUI - AXGN | 30% Poorly correlated | -1.66% | ||
More | ||||
XRAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
|---|---|---|---|---|
| XRAY | 100% | +1.41% | ||
| NVST - XRAY | 62% Loosely correlated | -0.34% | ||
| ALGN - XRAY | 58% Loosely correlated | -0.20% | ||
| QDEL - XRAY | 50% Loosely correlated | -1.31% | ||
| KIDS - XRAY | 48% Loosely correlated | -0.83% | ||
| STE - XRAY | 46% Loosely correlated | -0.71% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BITX | 18.00 | 0.36 | +2.04% |
| Volatility Shares 2x Bitcoin ETF (BITX) | |||
| GSC | 63.27 | 0.68 | +1.09% |
| Goldman Sachs Small Cap Equity ETF (GSC) | |||
| ENHI | 26.61 | 0.17 | +0.64% |
| iShares Enhanced International Active ETF (ENHI) | |||
| BRIB | 24.46 | 0.03 | +0.12% |
| FIS Bright Portfolios Core Bond ETF (BRIB) | |||
| BBYY | 8.19 | 0.01 | +0.07% |
| GraniteShares YieldBOOST BABA ETF (BBYY) | |||